Italia markets close in 7 hours 34 minutes

Valerio Therapeutics Société anonyme (0NWK.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,1229-0,1496 (-54,90%)
In data: 06:55PM BST. Mercato aperto.

Valerio Therapeutics Société anonyme

49, Bd du Général Martial Valin
Paris 75015
France
33 1 45 58 76 00
https://valeriotx.com

Settore/i
Settore
Impiegati a tempo pieno

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Shefali Agarwal M.D., MPHPresident, CEO & ChairwomanN/DN/D1973
Ms. Joyce CareyExecutive Director of Finance and Head of FP&AN/DN/DN/D
Ms. Robin SutherlandVP & Global Head of Human ResourcesN/DN/DN/D
Mr. Michel ForestChief Pharmacist & Quality Assurance DirectorN/DN/DN/D
Ms. Huiping JiangSenior Vice President of Regulatory Affairs & Quality AssuranceN/DN/DN/D
Mr. Wael Jdey Ph.D.Head of PreclinicalN/DN/DN/D
Dr. Donna Cabral-Lilly Ph.D.VP & Head of CMCN/DN/DN/D
Ms. Pam SlatcherHead of Global PVN/DN/DN/D
Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.

Governance aziendale

L'ISS Governance QualityScore di Valerio Therapeutics Société anonyme al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.